



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION




Preladenant

Item No. 22210

CAS Registry No.: 377727-87-2
Formal Name: 2-(2-furanyl)-7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine

Synonym: SCH 420814
MF: C₂₅H₂₉N₉O₃
FW: 503.6
Purity: ≥98%
UV/Vis.: λ_{max}: 259 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Preladenant is supplied as a crystalline solid. A stock solution may be made by dissolving the preladenant in the solvent of choice, which should be purged with an inert gas. Preladenant is slightly soluble in ethanol and DMSO.

Description

Preladenant is an orally bioavailable antagonist of the adenosine A_{2A} receptor (K_is = 1.1 and 2.5 nM for human and rat receptors, respectively).¹ It is selective for A_{2A} receptors over A₁, A_{2B}, and A₃ receptors (K_is = >1,000, >1,700, and >1,000 nM, respectively) as well as a panel of 59 receptors, enzymes, and ion channels. Preladenant inhibits adenylate cyclase activity (K_is = 1.3 and 0.7 nM for human and rat receptors, respectively) induced by the A_{2A} receptor agonist CGS 21680 (Item No. 17126). It inhibits catalepsy induced by haloperidol (Item No. 12014) in rats by 77 and 70% after 1 and 4 hours, respectively, when administered at a dose of 1 mg/kg. Preladenant also increases the efficacy of L-DOPA (Item No. 13248) when used in combination with eltopazine (Item No. 18428) in a 6-OHDA rat lesion model of Parkinson's disease dyskinesia.²

References

1. Neustadt, B.R., Hao, J., Lindo, N., *et al.* Potent, selective, and orally active adenosine A_{2A} receptor antagonists: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines. *Bioorg. Med. Chem. Lett.* **17**(5), 1376-1380 (2007).
2. Pinna, A., Kin, W., Costa, G., *et al.* Antidyskinetic effect of A_{2A} and 5HT_{1A/1B} receptor ligands in two animal models of Parkinson's disease. *Mov. Disord.* **31**(4), 501-511 (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/10/2018

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM